Exercise in muscle glycogen storage diseases

Journal of Inherited Metabolic Disease

Volumn 38, Issue 3, 2015, Pages 551-563

  Preisler, Nicolai ^a   Haller, Ronald G ^b,c,d   Vissing, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d Institute for Exercise and Environmental Medicine Dallas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOGEN;

CARBOHYDRATE METABOLISM; CLASSIFICATION; EXERCISE; EXERCISE TOLERANCE; GLYCOGEN STORAGE DISEASE; HUMAN; LIPID METABOLISM; METABOLISM; QUALITY OF LIFE; SKELETAL MUSCLE;

CARBOHYDRATE METABOLISM; EXERCISE; EXERCISE TOLERANCE; GLUCOSE; GLYCOGEN; GLYCOGEN STORAGE DISEASE; HUMANS; LIPID METABOLISM; MUSCLE, SKELETAL; QUALITY OF LIFE;

EID: 84939992894     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9771-y     Document Type: Article

References (85)

1. Ainsworth BE, Haskell WL, Herrmann SD et al (2011) 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc 43:1575–1581
2. Andersen ST, Haller RG, Vissing J (2008) Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 65:786–789
3. Baethmann M, Straub V, & Reuser AJ (2008) Pompe disease, 1st edn., pp 8-104. UNI-MED, Bremen
4. Bassett DR Jr, Howley ET (2000) Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc 32:70–84
5. Bembi B, Cerini E, Danesino C et al (2008) Diagnosis of glycogenosis type II. Neurology 71:S4–S11
6. Blair SN, Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA (1995) Changes in physical fitness and all-cause mortality. a prospective study of healthy and unhealthy men. JAMA 273:1093–1098
7. Chasiotis D, Sahlin K, Hultman E (1982) Regulation of glycogenolysis in human muscle at rest and during exercise. J Appl Physiol 53:708–715
8. Coleman RA, Stajich JM, Pact VW, Pericak-Vance MA (1986) The ischemic exercise test in normal adults and in patients with weakness and cramps. Muscle Nerve 9:216–221
9. Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT (1992) Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med 116:896–900
10. Cory JG (2006) Purine and pyrimidine nucleotide metabolism. In: Devlin TM (ed) Textbook of biochemistry: with clinical correlations. Wiley-Liss, Hoboken, pp 789–822
11. DiMauro S, Lamperti C (2001) Muscle glycogenoses. Muscle Nerve 24:984–999
12. DiMauro S, Hartwig GB, Hays A et al (1979) Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol 5:422–436
13. DiMauro S, Miranda AF, Khan S, Gitlin K, Friedman R (1981) Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy. Science 212:1277–1279
14. DiMauro S, Hays AP, Tsujino S (2004) Metabolic disorders affecting muscle. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1535–1558
15. Ding JH, De BT, De BT, Brown BI, Coleman RA, Chen YT (1990) Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III. J Pediatr 116:95–100
16. Echaniz-Laguna A, Akman HO, Mohr M et al (2010) Muscle phosphorylase b kinase deficiency revisited. Neuromuscul Disord 20:125–127
17. Haller RG, Lewis SF (1991) Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 324:364–369
18. Haller RG, Vissing J (2002) Spontaneous “second wind” and glucose-induced second “second wind” in McArdle disease: oxidative mechanisms. Arch Neurol 59:1395–1402
19. Haller RG, Vissing J (2004a) Functional evaluation of metabolic myopathies. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 665–679
20. Haller RG, Vissing J (2004b) No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 62:82–86
21. Haller RG, Lewis SF, Cook JD, Blomqvist CG (1985) Myophosphorylase deficiency impairs muscle oxidative metabolism. Ann Neurol 17:196–199
22. Haller RG, Wyrick P, Taivassalo T, Vissing J (2006) Aerobic conditioning: an effective therapy in McArdle’s disease. Ann Neurol 59:922–928
23. Harris RA (2006) Carbohydrate metabolism I: major metabolic pathways and their control. In: Devlin TM (ed) Textbook of biochemistry with clinical correlations. Wiley-Liss, New York, pp 581–635
24. Harris RA, Crabb DW (2006) Metabolic interrelationships. In: Devlin TM (ed) Textbook of biochemistry: with clinical correlations. Wiley-Liss, Hoboken, pp 849–890
25. Hermansen L, Hultman E, Saltin B (1967) Muscle glycogen during prolonged severe exercise. Acta Physiol Scand 71:129–139
26. Hers HG (1963) alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe’s disease). Biochem J 86:11–16
27. Hogrel JY, Laforet P, Ben YR, Chevrot M, Eymard B, Lombes A (2001) A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 56:1733–1738
28. Kazemi-Esfarjani P, Skomorowska E, Jensen TD, Haller RG, Vissing J (2002) A nonischemic forearm exercise test for McArdle disease. Ann Neurol 52:153–159
29. Kishnani PS, Austin SL, Arn P et al (2010) Glycogen storage disease type III diagnosis and management guidelines. Genet Med 12:446–463
30. Laforet P, Weinstein DA, Smit PA (2012) The glycogen storage diseases and related disorders. In: Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases. Springer, Berlin Heidelberg, pp 115–139
31. Lewis SF, Vora S, Haller RG (1991) Abnormal oxidative metabolism and O2 transport in muscle phosphofructokinase deficiency. J Appl Physiol 70:391–398
32. Lucia A, Nogales-Gadea G, Perez M, Martin MA, Andreu AL, Arenas J (2008) McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol 4:568–577
33. Lucia A, Ruiz JR, Santalla A et al (2012) Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry 83:322–328
34. Marzorati M, Porcelli S, Bellistri G, Morandi L, Grassi B (2012) Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy. Neuromuscul Disord 22(3):S230–S234. doi:10.1016/j.nmd.2012.10.017, S230-S234
35. Mate-Munoz JL, Moran M, Perez M et al (2007) Favorable responses to acute and chronic exercise in McArdle patients. Clin J Sport Med 17:297–303
36. McAlpine PJ, Hopkinson DA, Harris H (1970) The relative activities attributable to the three phosphoglucomutase loci (PGM1, PGM2, PGM3) in human tissues. Ann Hum Genet 34:169–175
37. McArdle WD, Katch FI, Katch VL (2007a) Energy transfer in the body. In: McArdle WD, Katch FI, Katch VL (eds) Exercise physiology: energy, nutrition, & human performance. Lippincott Williams & Wilkins, Baltimore, pp 137–163
38. McArdle WD, Katch FI, Katch VL (2007b) Individual differences and measurement of energy capacities. In: McArdle WD, Katch FI, Katch VL (eds) Exercise physiology: energy, nutrition & human performance. Lippincott Williams & Wilkins, Baltimore, pp 229–253
39. Moses SW, Gadoth N, Bashan N, Ben-David E, Slonim A, Wanderman KL (1986) Neuromuscular involvement in glycogen storage disease type III. Acta Paediatr Scand 75:289–296
40. Nadaj-Pakleza AA, Vincitorio CM, Laforet P et al (2009) Permanent muscle weakness in McArdle disease. Muscle Nerve 40:350–357
41. Naini A, Toscano A, Musumeci O, Vissing J, Akman HO, DiMauro S (2009) Muscle phosphoglycerate mutase deficiency revisited. Arch Neurol 66:394–398
42. Nakajima H, Raben N, Hamaguchi T, Yamasaki T (2002) Phosphofructokinase deficiency; past, present and future. Curr Mol Med 2:197–212
43. Nilsson MI, Samjoo IA, Hettinga BP et al (2012) Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab 107:469–479
44. Oh SJ, Park KS, Ryan HF Jr, Danon MJ, Lu J, Naini AB, DiMauro S (2006) Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency. Muscle Nerve 34:572–576
45. Ollivier K, Hogrel JY, Gomez-Merino D, Berkani M, Eymard B, Portero P (2005a) Effects of an endurance training on patients with McArdle’s disease. Sci Sports 20:21–26
46. Ollivier K, Hogrel JY, Gomez-Merino D et al (2005b) Exercise tolerance and daily life in McArdle’s disease. Muscle Nerve 31:637–641
47. Ono A, Kuwajima M, Kono N et al (1995) Glucose infusion paradoxically accelerates degradation of adenine nucleotide in working muscle of patients with glycogen storage disease type VII. Neurology 45:161–164
48. Orngreen MC, Schelhaas HJ, Jeppesen TD et al (2008) Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 70:1876–1882
49. Orngreen MC, Jeppesen TD, Andersen ST et al (2009) Fat metabolism during exercise in patients with McArdle disease. Neurology 72:718–724
50. Pearson CM, Rimer DG, Mommaerts WF (1961) A metabolic myopathy due to absence of muscle phosphorylase. Am J Med 30:502–517
51. Pedersen BK, Saltin B (2006) Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports 16(1):3–63
52. Perez B, Medrano C, Ecay MJ, Ruiz-Sala P, Martinez-Pardo M, Ugarte M, Perez-Cerda C (2013) A novel congenital disorder of glycosylation type without central nervous system involvement caused by mutations in the phosphoglucomutase 1 gene. J Inherit Metab Dis 36:535–542
53. Peronnet F, Massicotte D (1991) Table of nonprotein respiratory quotient: an update. Can J Sport Sci 16:23–29
54. Preisler N, Laforet P, Madsen KL et al (2012a) Fat and carbohydrate metabolism during exercise in late-onset Pompe disease. Mol Genet Metab 107:462–468
55. Preisler N, Orngreen MC, Echaniz-Laguna A et al (2012b) Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease? Neurology 78:265–268
56. Preisler N, Laforet P, Echaniz-Laguna A (2013a) Fat and carbohydrate metabolism during exercise in phosphoglucomutase type 1 deficiency. J Clin Endocrinol Metab 98:E1235–E1240
57. Preisler N, Pradel A, Husu E et al (2013b) Exercise intolerance in glycogen storage disease type III: weakness or energy deficiency? Mol Genet Metab 109:14–20
58. Quinlivan R, Vissing J, Hilton-Jones D, & Buckley J (2011) Physical training for McArdle disease. Cochrane Database Syst Rev CD007931
59. Richter EA, Hargreaves M (2013) Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev 93:993–1017
60. Rodriguez NR, Di Marco NM, Langley S (2009) American college of sports medicine position stand. nutrition and athletic performance. Med Sci Sports Exerc 41:709–731
61. Sacconi S, Wahbi K, Theodore G et al (2014) Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease. Neuromuscul Disord 24:648–650
62. Sakoda S, Shanske S, DiMauro S, Schon EA (1988) Isolation of a cDNA encoding the B isozyme of human phosphoglycerate mutase (PGAM) and characterization of the PGAM gene family. J Biol Chem 263:16899–16905
63. Shanske S, Sakoda S, Hermodson MA, DiMauro S, Schon EA (1987) Isolation of a cDNA encoding the muscle-specific subunit of human phosphoglycerate mutase. J Biol Chem 262:14612–14617
64. Slonim AE, Bulone L, Goldberg T et al (2007) Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 35:70–77
65. Smith TE (2006) Molecular cell biology. In: Devlin TM (ed) Textbook of biochemistry: with clinical correlations. Wiley-Liss, Hoboken, pp 949–1011
66. Stein TP, Wade CE (2005) Metabolic consequences of muscle disuse atrophy. J Nutr 135:1824S–1828S
67. Stojkovic T, Vissing J, Petit F et al (2009) Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med 361:425–427
68. Straub V (2008) Diagnosis. In Pompe Disease pp. 47-58. UNI-MED Verlag AG, D-28323 Bremen
69. Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97
70. Tegtmeyer LC, Rust S, Van SM (2014) Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med 370:533–542
71. Terzis G, Dimopoulos F, Papadimas GK et al (2011) Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab 104:279–283
72. Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P (2012) Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab 107:669–673
73. Thompson WR, Gordon NF, Pescatello LS (2010) Pre-exercise evaluations. In: Thompson WR, Gordon NF, Pescatello LS (eds) ACSM’s guidelines for exercise testing and prescription. Kluwer & Lippincott Williams & Wilkins, Baltimore, pp 42–59
74. van den Berg LE (2014). The musculoskeletal system in Pompe disease: pathology, consequences and treatment options. Dissertation, Erasmus Universiteit Rotterdam.
75. van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353
76. van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406
77. van der Ploeg AT, Barohn R, Carlson L et al (2012) Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa. Mol Genet Metab 107:456–461
78. van Hoof F, Hers HG (1967) The subgroups of type 3 glycogenosis. Eur J Biochem 2:265–270
79. van Loon LJ, Greenhaff PL, Constantin-Teodosiu D, Saris WH, Wagenmakers AJ (2001) The effects of increasing exercise intensity on muscle fuel utilisation in humans. J Physiol 536:295–304
80. Vissing J, Haller RG (2003) The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N Engl J Med 349:2503–2509
81. Vissing J, Orngreen M (2014) Metabolic myopathies. In: Hilton-Jones D, Turner MR (eds) Oxford texbook of neuromuscular disorders. Oxford University Press, Oxford, pp 288–301
82. Vissing J, Galbo H, Haller RG (1996) Paradoxically enhanced glucose production during exercise in humans with blocked glycolysis caused by muscle phosphofructokinase deficiency. Neurology 47:766–771
83. Vissing J, Quistorff B, Haller RG (2005) Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol 62:1440–1443
84. Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts AC (2013) Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 7:CD003907. doi:10.1002/14651858, CD003907.pub4., CD003907
85. Wuyts W, Reyniers E, Ceuterick C, Storm K, De BT, Martin JJ (2005) Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene. Am J Med Genet A 133A:82–84